Market Data Browsing: Aurobindo
Aurobindo Pharma (NS:) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year…
Aurobindo Pharma (NS:) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year…